Android app on Google Play

Endo Pharmaceuticals Holdings (ENDP) Tops Q4 EPS by 7c, Reaffirms Outlook

February 28, 2013 4:13 PM EST Send to a Friend
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q4 EPS of $1.62, $0.07 better than the analyst estimate of $1.55. Revenue for the quarter came in at $801.1 million versus the consensus estimate of $807.98 million. Endo Pharmaceuticals Holdings reaffirmed FY2013 guidance.

For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.




You May Also Be Interested In


Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment